Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) Target Price at $15.33

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has earned an average rating of “Hold” from the twelve ratings firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $15.3333.

Several research firms recently commented on AARD. B. Riley Financial reduced their price objective on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Friday, May 15th. HC Wainwright restated a “neutral” rating and set a $6.00 target price on shares of Aardvark Therapeutics in a research note on Monday, July 20th. Weiss Ratings raised shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. Wall Street Zen upgraded shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, BTIG Research cut shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th.

Aardvark Therapeutics Trading Up 5.4%

Aardvark Therapeutics stock opened at $6.10 on Friday. The firm has a market cap of $133.47 million, a price-to-earnings ratio of -1.90 and a beta of 3.80. The stock has a fifty day simple moving average of $6.26 and a two-hundred day simple moving average of $5.93. Aardvark Therapeutics has a 12 month low of $3.35 and a 12 month high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.21. On average, equities research analysts forecast that Aardvark Therapeutics will post -3.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Aardvark Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Aardvark Therapeutics during the 2nd quarter valued at $42,000. Persistent Asset Partners Ltd purchased a new position in shares of Aardvark Therapeutics in the 4th quarter worth $56,000. New York State Common Retirement Fund purchased a new position in shares of Aardvark Therapeutics in the 2nd quarter worth $99,000. MetLife Investment Management LLC bought a new stake in shares of Aardvark Therapeutics in the fourth quarter worth $102,000. Finally, Bank of America Corp DE grew its holdings in shares of Aardvark Therapeutics by 72.9% in the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after acquiring an additional 3,369 shares during the period.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.